Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona

Nanoscope Therapeutics Announces Presentations at Euretina Innovation Spotlight and Ophthalmology Futures Forum in Barcelona

DALLAS, Sept. 16, 2024  — Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, and geographic atrophy today announced presentations at the Euretina Innovation Spotlight and at Ophthalmology Futures Forum taking place on 18th September in Barcelona, Spain. Details for the presentations are as follows:

Title: Breakthrough in Vision Restoration: Mutation-agnostic Optogenetics for Inherited Retinal Diseases and Geographic Atrophies
Session Title: Nonneovascular AMD and IRDs
Session Date: September 18, 2024
Session Time: 14:35 p.m. CEST
Location: Barcelona International Convention Center
Presenter: Samuel Barone, MD, Chief Medical Officer

In his presentation followed by a panel discussion, Dr. Barone will highlight the Multi-Characteristic Opsin (MCO) therapy pipelines of Nanoscope for the treatment of severe vision loss due to retinitis pigmentosa, Stargardt macular degeneration, and geographic atrophy.

Title: Democratizing Gene Therapy for Retinal Degenerative Diseases
Session Title: Company Presentations 3
Session Date: September 18, 2024
Session Time: 17:55 p.m. CEST
Location: Esferic Barcelona
Presenter: Samarendra Mohanty, PhD, President & Chief Scientific Officer

During his presentation, Dr. Mohanty will highlight the mutation-agnostic optogenetic gene therapy for vision restoration in inherited retinal dystrophies, and geographic atrophy. He will also participate in a panel discussion, chaired by Prof. Dominik Fischer, Professor at the University of Oxford.

Panel Title: Gene & Cell Therapy Outlook for Back of the Eye Diseases: Is this Really a Business?
Panel Date: September 18, 2024
Panel Time: 18:40 – 19:10 p.m. CEST
Location: Esferic Barcelona
Panelist: Samarendra Mohanty, PhD, President & Chief Scientific Officer

Both these events include networking opportunities with industry leaders, clinicians, innovators, regulators, and investors. The management team will be in attendance at these events and accessible for meetings.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, recently reported topline results from the RESTORE Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trial in the U.S. for retinitis pigmentosa (NCT04945772). The company has also completed the Phase 2 STARLIGHT trial  of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designations and FDA orphan drug designations for both RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Investor Contact:
Argot Partners
(212) 600-1902
PR@nanostherapeutics.com

SOURCE Nanoscope Therapeutics

On September 16, 2024   /   Nanoscope Press Release, Home Page  
Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186

  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.